Targeting tumor-necrosis factor receptor pathways for tumor immunotherapy

David A Schaer1,5†, Daniel Hirschhorn-Cymerman1† and Jedd D Wolchok1,2,3,4*

Abstract

With the success of ipilimumab and promise of programmed death-1 pathway-targeted agents, the field of tumor immunotherapy is expanding rapidly. Newer targets for clinical development include select members of the tumor necrosis factor receptor (TNFR) family. Agonist antibodies to these co-stimulatory molecules target both T and B cells, modulating T-cell activation and enhancing immune responses. In vitro and in vivo preclinical data have provided the basis for continued development of 4-1BB, OX40, glucocorticoid-induced TNFR-related gene, herpes virus entry mediator, and CD27 as potential therapies for patients with cancer. In this review, we summarize the immune response to tumors, consider preclinical and early clinical data on select TNFR family members, discuss potential translational challenges and suggest possible combination therapies with the aim of inducing durable antitumor responses.

Keywords: Cancer, Immunotherapy, 4-1BB, OX40, GITR

Introduction

After nearly a century of skepticism regarding the efficacy of immunotherapy in cancer, a resurgence has begun that is driven primarily by the success of ipilimumab [1]. The immune-mediated mechanism of action and resultant antitumor activity of ipilimumab lend support to the notion that tumors are under immune surveillance. Moreover, the concept of “immuno-editing” suggests that the pressure exerted on tumors by the immune system shapes or “edits” tumor cells, allowing their escape from immune elimination [2]. Briefly, the immune system is capable of eliminating malignant cells during initial transformation. As tumors grow, an “equilibrium” is reached where immune tumor growth is matched by immune-mediated tumor destruction. Eventually, malignant cells either accumulate mutations, making them non-immunogenic, or immunosuppressive pathways become activated, allowing the tumor to escape immune recognition [2-5]. It now appears that targeting immunomodulatory mechanisms can tip the balance from escape back toward elimination. In addition to ipilimumab and other co-inhibitory checkpoints (i.e., programmed death-1 [PD-1]), research into the stimulation of T cell responses via agonist therapies has opened another therapeutic possibility. This review will focus on the rationale for targeting co-stimulatory pathways in T cells, summarize agents in development, and offer possible treatment strategies using these agents in combination with other immunotherapies.

Review

The host response to tumors has been well described [6-9]. However, tumors have developed ways to escape this response via a number of mechanisms; these have been extensively reviewed previously [6-8,10]. The accumulation of suppressive cells and an inhibitory cytokine milieu in and around the tumor can form an immunosuppressive environment that prevents successful T cell-mediated destruction of malignant cells [11]. The goal of many immunotherapies is to help the immune system overcome the mechanisms that tumors employ to evade destruction.

Targeting immune “checkpoint” pathways

Upon initial activation by antigen-presenting cells (APCs), tumor-specific T cells receive essential co-stimulation through binding of CD28 to CD80/86 on activated APCs. However, the CD28-CD80/86 pathway is antagonized by
cytotoxic T lymphocyte antigen-4 (CTLA-4; CD152), one of the first co-inhibitory checkpoints that self-limit responses. CTLA-4 competes with CD28 for CD80/86 binding and has a much greater affinity than CD28 for CD80; CTLA-4 signaling decreases the magnitude of early T-cell activation, expansion, and function [12-14]. Ipilimumab blocks CTLA-4 antagonism of CD28 and was the first agent to demonstrate an overall survival benefit for patients with metastatic melanoma [1,15]. The ability of CTLA-4 blockade to enhance tumor immunity may be because most tumor antigens are modified self-antigens or mutated unique antigens against which T cell cytotoxic function is believed to be relatively poor. Therefore, by releasing this first brake on immune activation, ipilimumab allows the generation of a more effective immune response [16].

Subsequent to CTLA-4, PD-1 was also shown to regulate the immune response. PD-1 interacts with B7-homolog 1 (B7-H1 or programmed death receptor-1 ligand1 [PD-L1]) and B7-DC (PD-L2) on APCs and tumor cells. Ligation of PD-1 by either of its ligands downregulates T-cell receptor (TCR) signaling and abrogates stimulatory cytokine production [17,18]. Moreover, PD-1 upregulation on effector T cells identifies T cells with an exhausted phenotype that cannot maintain polyfunctional cytokine production [19]. Although the evaluation of PD-1/PD-L1–targeted therapies is at an early stage, they are showing promising results. Evaluation of the anti–PD-1 antibody nivolumab in more than 300 patients in a phase I trial, showed antitumor activity in patients with non-small cell lung cancer (NSCLC), renal cell carcinoma (RCC), and melanoma, and an encouraging safety profile [20,21]. Combination of nivolumab with ipilimumab has also demonstrated a potentially synergistic effect in a recent phase I combination study for patients with advanced melanoma [22]. Phase III trials in these tumors are ongoing. The anti–PD-1 antibody CT-011 has shown activity in a small phase I trial of patients with various hematological malignancies [23]. Data with other anti–PD-1 and anti–PD-L1 antibodies and fusion proteins are becoming available [24-27].

**TNFR superfamily costimulatory molecules**

In addition to blocking co-inhibitory pathways, activating co-stimulatory pathways to potentiate antitumor immune responses is a promising approach. Members of the necrosis factor receptor superfamily (TNFRsf) include several co-stimulatory proteins with key roles in B and T cell development, survival, immune activation, and antitumor immune responses [28]. These co-stimulatory TNFRsf members lack death domains, enabling them to enhance activation and proinflammatory cascades [29], making them attractive therapeutic targets (Table 1). Recent clinical success with checkpoint inhibitors has provided the rationale for investigating agonism of 4-1BB (CD137), OX40, glucocorticoid-induced TNFR-related gene (GITR), herpes virus entry mediator (HVEM), and CD27 in order to extend clinical benefit to more patients.

**4-1BB (CD137)**

4-1BB is a molecule with profound effects on T-cell proliferation and CD8+ T-cell function [30-32]. It is primarily present on activated but not resting T cells, activated natural killer (NK) cells, and natural killer T (NKT) cells. It is expressed constitutively on certain populations of dendritic cells (DCs) and regulatory T cells (Tregs) [33-36]; 4-1BB expression is upregulated on monocytes upon activation [35]. Stimulation of 4-1BB by either its natural ligand, 4-1BBL, or by agonist antibodies enhances the activation of various immune cells, including T cells, DC (upregulation of B7 molecules and immunostimulatory cytokine production), monocytes, and neutrophils (proinflammatory cytokine secretion), and induces a

---

**Table 1 TNFR-targeted agents in development**

| TNF receptor molecule | Name          | Description                                      | Sponsor                      | Phase in cancer patients |
|-----------------------|---------------|--------------------------------------------------|------------------------------|--------------------------|
| 4-1BB (CD137)         | CART19 cells  | T cells transduced with antibody against CD19 linked to the intracellular signaling domains of 4-1BB and CD3-zeta | University of Pennsylvania and others | II                       |
|                       | Urelumab     | Fully human anti-CD137 agonist monoclonal antibody | Bristol Myers-Squibb         | I                        |
|                       | OX40         | Mouse monoclonal anti-OX40 agonist antibody      | Providence Health & Services and others | II                       |
|                       | hFcLZOX40L   | Humanized antibody against OX40                   | Providence Portland Medical Center | Preclinical              |
|                       | GITR         | TRX518 Humanized anti-GITR agonist monoclonal antibody | GITE, Inc.                  | I                        |
|                       | GITRL RNA    | GITRL-expressing DCs                             | Duke University              | I                        |
|                       | CD27         | CDX-1127 Fully human anti-CD27 agonist monoclonal antibody | Celldex Therapeutics         | I                        |

Abbreviation: DCs Dendritic Cells, GITR Glucocorticoid-Induced TNFR-Related Gene, GITRL GITR Ligand, TNF Tumor-Necrosis Factor, TNFR Tumor-Necrosis Factor Receptor.
spectrum of effects on B and NK cells [35,36]. 4-1BB signaling can co-stimulate T cells in a CD28-independent manner [37], protect tumor-infiltrating lymphocytes (TILs) from activation-induced cell death (AICD) via upregulation of antiapoptotic pathways [38,39], and enhance cytotoxic T lymphocyte (CTL) survival and cytolytic activity [40].

Preclinical data show that targeting 4-1BB with an agonist antibody can promote tumor control in numerous preclinical models, and is often associated with increased CTL effector capability [36,41-43]. The effects of pairing agonist anti–4-1BB antibodies with other therapies have also been investigated. Anti-4-1BB antibody administered with adoptive T-cell therapy resulted in survival and resistance to rechallenge in 80% of mice bearing established thymomas [44]. Combining anti–4-1BB with an agonist anti–CD40 plus a blocking antibody against DR5, a receptor for TRAIL (a strategy termed “trimab”), had activity against multiple transplanted tumors in mice [45]. Adding anti–CTLA-4 further increased the potency of this approach, resulting in ~80% tumor rejection of established mammary 4 T1 tumors in mice [46]. Combining CTLA-4 blockade and 4-1BB co-stimulation with a granulocyte-macrophage colony-stimulating factor (GM-CSF)–secreting melanoma vaccine greatly improved tumor eradication and promoted survival compared with vaccine plus either agent [47]. Combination treatment increased proliferation and tumor infiltration by both CD4+ and CD8+ T cells, and intratumor inflammatory cytokine production. Likewise, a 4-1BBL–expressing RM-1 cell vaccine used with CTLA-4 blockade in mice bearing RM-1 prostate tumors improved survival compared with mice treated with monotherapy [48]. These data suggest that concurrent manipulation of the CTLA-4 and 4-1BB signaling pathways merits clinical evaluation.

Other combinations have also been investigated. Kohrt and colleagues showed human trastuzumab-activated NK cells had improved cytotoxicity against breast cancer cells when stimulated with an agonist 4-1BB antibody [49]. Agonistic anti–4-1BB antibodies also had antitumor activity when given together with radiation therapy in murine breast and lung cancer models and when combined with anti–PD-1 plus radiotherapy [50,51]. Finally, targeting 4-1BB with intratumoral interferon-α therapy or DC-based vaccination also produced significant antitumor responses and/or improved survival [52,53].

Against this background, agonist 4-1BB therapy with urelumab (BMS-663513) was investigated in patients with melanoma, RCC, and ovarian cancer. Although some antitumor activity was observed during a phase I trial, safety concerns halted development [54,55]. Development has recently restarted using urelumab at a lower dose in combination with other agents (NCT01471210 and NCT01775631, clinicaltrials.gov).

A different approach to utilizing the immune-potentiating properties of 4-1BB has been explored in the context of chimeric antigen receptor (CAR)–transduced T cells. Expressing an antibody with specificity for the B cell antigen CD19 linked to the intracellular signaling domains of 4-1BB and CD3ζ enhanced the survival and effector functions provided by transduced T cells directed against tumor cells. T cells with this modified CAR (termed “CART19” cells) infused into a patient with refractory chronic lymphocytic leukemia (CLL) induced complete disease remission that was ongoing for more than 10 months [56]. Clinical studies of CART19 cells in patients with various B cell leukemias and lymphomas are ongoing (clinicaltrials.gov).

**OX40 (CD134)**

OX40 (TNR4) [57] is similar to 4-1BB and GITR, and engagement promotes T-cell activation, survival, proliferation, and cytokine production [58-62]. OX40 is primarily expressed on activated CD4+ T cells 24–48 hours after activation, and on CD8+ T cells, neutrophils, dendritic cells, and Tregs [60,63]. The natural ligand of OX40, OX40 ligand (OX40L), is most common on APCs, and is also found on activated T cells. OX40 expression is induced by TCR stimulation, but co-stimulation through other molecules, such as CD28, or exposure to certain cytokines can further upregulate expression [64]. While OX40 has a key role in the development and function of Tregs, engagement of OX40 with an agonist antibody can also deactivate the suppressive function of Tregs [63,65-69].

OX40 agonism has been investigated in multiple tumor models. As a monotherapy, it delayed tumor growth in vivo and promoted the rejection of various tumors [60,62,70]. OX40-dependent antitumor immunity required both CD4+ and CD8+ T cells, and a significant proportion of treated mice remained tumor-free and resistant to rechallenge, supporting the notion that OX40 engagement promotes memory [71]. Combination approaches aimed at improving the efficacy of OX40 engagement have been explored. Combinations of anti-OX40 with fractionated radiotherapy, interleukin (IL)-12 and anti–4-1BB, anti–CTLA-4 and CpG oligonucleotides, anti–CD25 and anti–CTLA-4 with adoptive cell transfer, transforming growth factor (TGF)-β inhibition, or IL-2 improved antitumor responses, tumor rejection, long-term survival, and/or resistance to tumor rechallenge in mice bearing various cancers [64,71-75]. We have shown that combining anti-OX40 with cyclophosphamide led to the regression of the poorly immunogenic B16 murine melanoma and was associated with fewer intratumoral Tregs, leading to a favorable effector/Treg cell ratio within the tumor microenvironment [76]. Adoptive transfer of melanoma specific CD4+ T cells together with OX40 and cyclophosphamide eliminated even more advanced melanomas. This
combination triggered cytolytic activity in the transferred CD4+ T cells, a phenomenon largely responsible for the potency of this combination [76].

In the first-in-human clinical trial, 30 patients with solid tumors received a murine anti-human OX40 monoclonal antibody at doses from 0.1 through 2 mg/kg; the maximum tolerated dose was not identified, and some patients had an objective response after one dose [77]. Humanized OX40 antibodies and a fully human OX40L:IgG fusion protein have been developed [60,78,79]. Phase II clinical trials evaluating OX40 agonists with stereotactic radiation and/or cyclophosphamide in patients with multiple tumor types are ongoing (NCT01642290, NCT01303705).

**GITR (CD357)**

GITR is expressed at low levels on resting CD4+ and CD8+ T cells, is upregulated after 24–72 hours of stimulation, and remains expressed for several days [80-82]. In contrast to effector T cells, Tregs constitutively express GITR. GITR has also been observed on DC, monocytes, and NK cells. Similar to OX40 and 4-1BB, ligation provides co-stimulatory signals that enhance T-cell proliferation and effector function, and protect T cells from AICD [81,82]. GITR ligand (GITRL) is highly expressed on activated APCs and endothelial cells (ECs). Interestingly, while the role of GITRL on APCs appears primarily to provide costimulation, it was recently shown that GITRL/GITR interactions on EC may be important for triggering leukocyte adhesion and transmigration [83]. Although human and mouse GITR have similar characteristics, unlike most TNFR family members, murine GITR exists as a dimer instead of a trimer [84,85]. How this difference relates to the biological functions of mouse and human GITR is unknown.

Reports showing GITR ligation can break self-tolerance and abrogate T-cell suppression by Tregs identify it as a target for cancer immunotherapy [86,87]. Our laboratory was the first to demonstrate that an agonist anti-GITR antibody, the rat monoclonal DTA-1, could protect mice from B16 tumor rechallenge and that treatment induced rejection of small, established B16 tumors [88,89]. Stimulation of GITR also cured established sarcomas, induced long-lasting memory, and had activity in other mouse models [82,90]. GITRL manipulation has also been explored. Mice bearing GITRL-expressing tumors had improved CTL effector function and peritumoral injection of a GITRL vaccine slowed the growth of established tumors [91].

Multiple mechanisms appear to contribute to the antitumor effects of GITR modulation. We have demonstrated that DTA-1 administration impaired intratumoral Treg expression of FoxP3, resulting in a loss of Treg lineage stability and abrogation of intratumor Treg suppressive function [92]. This led to a higher effector T cell (Teff):Treg ratio and improved antitumor CTL function [88]. Additionally, Côté and colleagues found that DTA-1 treatment enhanced the development of high-avidity CTL responses to tumor-associated antigens in a mouse melanoma model [93]. Recent reports show that DTA-1 can cause depletion of intratumoral Tregs through interactions between the antibody and activating FcγRs on myeloid cells [94]. Because of differences in tumor models and underlying treatment conditions, it is unclear if one of these mechanisms is dominant or if all play a role in GITR agonist immunotherapy. The exact contribution of each will require further investigation.

GITR agonism (either via DTA-1 or GITRL fusion protein) has been successfully combined with other immunotherapies, including DNA- or DC-based vaccines [93,95-97]. Response to DTA-1 in mice bearing fibrosarcoma or colorectal carcinoma improved in combination with adoptive T-cell transfer or an antagonistic anti–CTLA-4 antibody [90,98,99]. Pruitt and colleagues saw improvements in antitumor immunity when a melanoma DC vaccine was combined with DCs expressing anti–CTLA-4 and anti-GITR mRNA [100].

While most reports show GITR-GITRL interactions are co-stimulatory to T cells, data regarding the immune-stimulating potential of GITR on non–T-cell subsets, particularly NK cells, are conflicting. Human leukemia cell expression of GITR-L interferes with NK cell-mediated immunity through reverse signaling, which causes tumor production of suppressive cytokines, downregulation of co-stimulatory molecules, and evasion from immune detection [101,102]. Nonetheless, in collaboration with Ludwig Cancer Research, Cancer Research Institute, and GITR, Inc. (Cambridge, MA, USA), we initiated a phase I trial (NCT01239134) of the humanized anti-GITR antibody TRX518 [103]. A trial examining the effects of GITRL-expressing DCs (with or without DC expressing anti–CTLA-4) plus a DC tumor vaccine in patients with melanoma is also ongoing (NCT01216436).

**HVEM (CD270)**

HVEM, another member of the TNFR superfamily [104], has multiple binding partners and various downstream effects that can positively and negatively modulate T-cell activation [105]. HVEM expression kinetics are the opposite of 4-1BB, OX40, and GITR: HVEM is highly expressed on resting T cells but downregulated upon activation. When cells return to less-activated states, HVEM expression is restored. There is significant HVEM expression on naive and memory, but not activated, B cells. Other immune cells, including Tregs, NK cells, monocytes, and immature DCs, also express HVEM. There are at least four natural ligands for HVEM: the inhibitory Ig-related molecules CD160 and B and T lymphocyte attenuator (BTLA; capable of bidirectional signaling)
and the stimulatory TNF-related cytokines LIGHT and lymphotoxin-alpha [106-109]. LIGHT is expressed upon T and B cell activation and on monocytes and immature DCs. CD70 is found on various lymphoid and myeloid cells, with particularly high expression on B cells and plasmacytoid DCs. CD160, by contrast, is observed only on subsets of T and NK cells [105]. While binding of LIGHT or lymphotoxin-α to HVEM triggers T and B cell stimulation and APC maturation and differentiation, CD160 or BTLA binding to HVEM on T or B cells has the reverse effect, inhibiting T and B cell activation.

Studies have explored the potential of the HVEM pathway as a therapeutic target. Murine P815 mastocytoma cells engineered to express the single-chain variable fragment (scFv) of an anti-HVEM agonistic monoclonal antibody stimulated proliferation and cytokine production in co-cultured T cells [110]. Expression of anti-HVEM scFv in vivo resulted in T-cell-dependent tumor rejection (in 80% of treated mice) and a lasting memory response. Combination of the anti-HVEM scFv-expressing tumor vaccine with anti-4-1BB monoclonal antibody therapy synergized to induce regression of more established tumors, leading to survival and memory responses not seen with either agent alone [111]. In melanoma patients, tumor-specific T cells were found to express BTLA concurrent with HVEM [108,109]. Fourcade and colleagues tested the significance of this expression, showing that BTLA blockade enhanced the proliferation and antitumor activity of melanoma-specific CD8+ T cells [109]. Approaches to mono- or combination therapy are presented in the review by Pasero and colleagues [105]. However, manipulating the HVEM signaling pathway(s) provides a significant challenge, requiring agents that precisely induce HVEM-related immunostimulatory effects or block HVEM-related immunosuppressive effects.

CD27

CD27 has a key role in the generation of immunological memory via effects on T-cell expansion and survival, and B cell development [112-114]. CD27 is constitutively expressed on conventional T cells (including populations of Tregs) and, like other members of the TNFRsf, is up-regulated upon activation [115]. Expression of CD27 on human Tregs correlates with FoxP3 expression and suppressive functionality [116,117]. CD27 is also expressed on subsets of B cells, most strikingly on plasma cells, for which it is a broadly accepted marker [118]. CD70, the natural ligand for CD27, is transiently expressed on activated APCs and T cells [119]. Ligation of CD27 by CD70 has stimulatory effects on T-cell proliferation, expansion, and survival dependent upon IL-2 autocrine signaling [120].

Triggering CD27 signaling in CAR-transduced T cells can enhance effector function, survival, and improve antitumor activity in a xenograft mouse model of ovarian cancer [121]. Constitutive CD70 expression on tumors or DCs improved antitumor immunity in murine lymphoma models, enhancing NK-mediated rejection of class-I deficient tumor cells via perforin- and IFN-γ-dependent mechanisms [122]. CD70 expression also leads to generation of memory T-cell response to secondary tumor challenge. Conversely, intact CD27/CD70 signaling has been associated with decreased antitumor immune responses and an increased intratumoral Tregs (potentially due to improved Treg resistance to apoptosis and increased IL-2 secretion by effector T cells). Compared with wild-type mice, tumors in CD72-deficient mice had decreased vascularization and slower growth [123]. Furthermore, wild-type mice treated with an anti-CD27 blocking antibody had fewer Tregs and slower tumor growth than untreated mice. In this setting, Tregs were critical mediators of CD27-dependent effects on tumor growth. Schurch and colleagues similarly demonstrated that CD27 triggering by CD70 ligation in chronic myelogenous leukemia stem cells accelerated disease progression and was associated with activation of the Wnt pathway [124]. Such data complicate the consideration of CD27 as a target for tumor immunotherapy. The effects of CD27 pathway triggering may depend upon the environment in which the stimulus is delivered—within the tumor microenvironment or in peripheral lymphoid tissues—as well as length of exposure to stimulating agents.

A fully human monoclonal CD27 agonist antibody, CDX-1127 (Celldex Therapeutics, Inc. Needham, MA, USA), is being evaluated in a phase I clinical trial in select hematological and solid tumors [125]. Preclinical experiments with a mouse homologue showed delayed human hematological tumor growth in xenograft mouse models and murine tumor growth in immunocompetent mice [126]. Again, similar to HVEM, continued clinical development of CD27-related agents will require teasing apart the multiple inhibitory and co-stimulatory mechanisms that target multiple cell populations, and precise triggering of certain molecules in select environments to avoid exaggerating tumor-induced immunosuppression. Since Tregs appear to be a critical target of CD27 agonism, perhaps prior Treg depletion may be appropriate.

Conclusions

The success of cancer immunotherapy with agonist antibodies may vary according to tumor type, since the expression of the target molecules can differ across tumors (for example, the expression of HVEM in certain leukemias and lymphomas). Although a multifactorial approach to cancer therapy is attractive [127], the potential risk of autoimmune reactions and bystander tissue damage in the setting of immunostimulation should not be underestimated. The well-documented phase I
study of the anti-CD28 monoclonal antibody TGN1412, in which six healthy volunteers suffered massive cytokine release and major organ damage, emphasized the need for extreme caution in trial design and execution when investigating immune activators [128]. It should be noted, however, that CD28 is constitutively expressed on T cells, whereas most of the TNFRsf members are up-regulated upon activation. Therefore, targeting TNFRsf members might have more restricted downstream effects, including a more defined toxicity profile. Targeting the co-stimulatory TNFRsf shows promise for the treatment of cancer. Although there have been life-threatening side effects with some agonist antibodies, there is obvious clinical activity, emphasizing the need for extreme caution in trial design and execution. The mechanisms of immune evasion are not the same for each patient’s tumor (even of the same tumor type) and as such, monotherapies may not achieve sufficient potency. Combinatorial approaches, which include targeting TNFRsf, show promise in preclinical studies. Thus, combination with chemotherapy or irradiation, which can induce immunogenic cell death and stimulate antitumor T cells, is a rational. Additionally, combining anti-TNFRsf antibodies with small molecule inhibitors should be considered. Although clinical studies of TNFRsf agonists are at an early stage, careful development may see additional therapies brought to patients who most need them most.

Abbreviations
AICD: Activation-induced cell death; APCs: Antigen-presenting cells; B7-H1: B7-homolog 1; BTLA: B and T lymphocyte attenuator; CAR: Chimeric antigen receptor; CD137: 4-1BB; CLL: Chronic lymphocytic leukemia; CTL: Cytotoxic T lymphocyte; CTLA-4: Cytotoxic T lymphocyte antigen-4; DCs: Dendritic cells; ECS: Endothelial cells; GITR: Glucocorticoid-induced TNFR-related gene; GITRL: GITR ligand; GM-CSF: Granulocyte-macrophage colony-stimulating factor; HVEM: Herpes virus entry mediator; IL: Interleukin; MDSC: Myeloid-derived suppressor cells; NK: Natural killer; NKT: Natural killer T cells; NSCLC: Non-small cell lung cancer; OX40L: OX40 ligand; PD-1: Programmed death receptor-1; PD-L1/2: Programmed death receptor-1 ligand1/2; RCC: Renal cell carcinoma; scFv: Single-chain variable fragment; TCR: T-cell receptor; Teff: Effector T cell; TILs: Tumor-infiltrating lymphocytes; TNF: Tumor-necrosis factor; TNFR: Tumor necrosis factor receptor; TNFRsf: Tumor necrosis factor receptor superfamily; Treg: Regulatory T cell.

Competing interests
DS and DH declare no competing interest. JW discloses that he is a paid consultant for Medimmune and Bristol-Myers Squibb.

Authors’ contributions
DS, DH and JW contributed equally to the development of this manuscript. All authors read and approved the final manuscript.

Acknowledgments
This study was partially supported by NIH grants R01CA56821, P01CA33049, and P01CA93590, D.A.S received support from the NIH Clinical Training for Scholar Grant K12 CA121021-01, NH/NCI Immunology Training Grant T32 CA09149-30 and John D. Proctor Foundation: Margaret A. Cunningham Immune Mechanisms in Cancer Research Fellowship Award; Swim Across America; the Mr. William H. Goodwin and Mrs. Alice Goodwin and the Commonwealth Cancer Foundation for Research and the Experimental Therapeutics Center of Memorial Sloan-Kettering Cancer Center (to J.D.W.). Professional medical writing and editorial assistance was provided by Caillin Moira Wilke, PhD, at StemScientific, and was funded by Bristol-Myers Squibb.

Author details
1Swim Across America Laboratory, Immunology Program, Sloan-Kettering Institute for Cancer Research, New York, NY 10065, USA. 2Well Cornell Medical College, New York, NY 10065, USA. 3Ludwig Collaborative Lab, New York, NY 10065, USA. 4Ludwig Center for Cancer Immunotherapy at Memorial Sloan-Kettering Cancer Center, New York, NY 10065, USA. 5Current address: Department of Cancer Immunobiology, ImClone Systems, a wholly-owned subsidiary of Eli Lilly & Co, New York, NY 10016, USA.

Received: 16 January 2014 Accepted: 13 March 2014 Published: 15 April 2014

References
1. Hodi FS, O’Day SJ, McDermott DF, Weber RW, Sosman JA, Haanen JB, Gonzalez R, Robert C, Schadendorf D, Hassell JC, Akerley W, van den Eertwegh AJ, Lutzky J, Lotigan P, Vaubel JM, Linette GP, Hogg D, Otersmeier CH, Leblb C, Peschel C, Quint J, Ciszk B, Wolchok JD, Weber JS, Tian J, Yellin MJ, Nichol GM, Hoos H, Uta W. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 2010, 363:711–723. 2. DuPage M, Mazumdar C, Schmidt L, Cheung AF, Jack T. Expression of tumor-specific antigens underlies cancer immunoeediting. Nature 2012, 482:405–409. 3. Schreiber RD, Old LJ, Smyth MJ. Cancer immunoeediting: integrating immunity’s roles in cancer suppression and promotion. Science 2011, 331:1565–1570. 4. Dunn GP, Bruce AT, Ikeda H, Old LJ, Schreiber RD. Cancer immunoeediting: from immunosurveillance to tumor escape. Nat Immunol 2002, 3:991–998. 5. Matsushita H, Velky MD, Roboldt DC, Rickert CG, Uppaluri R, Magnini VJ, Arthur CD, White JM, Chen YS, Shea LS, Hundal J, Wendl NC, Derbrer R, Wyke T, Allison JP, Smyth MJ, Old LJ, Mardis EB, Schreiber RD. Cancer exome analysis reveals a T-cell-dependent mechanism of cancer immunoeediting. Nature 2012, 482:400–404. 6. Draghiciu DA, Nijman HV, Daemen T. From tumor immunosuppression to eradication: targeting homeostasis and immunity of active effector cell to tumors. Clin Dev Immunol 2011, 2011:93053. 7. Meltman J, Coulkos G, Dranoff G. Cancer immunotherapy comes of age. Nature 2011, 480:480–489. 8. Topper K, Kempe S, Mueller N, Schmitz M, Bachmann M, Cantelli-M, Schackert G, Termne A. Tumor evasion from T cell surveillance. J Immunobiol 2011, 2011:518471. 9. Fuertes MB, Kacha AK, Kline J, Woo SR, Kranz DM, Murphy KM, Gajewski TF, Arthur CD, White JM, Chen YS, Shea LS, Hundal J, Wendl NC, Derbrer R, Wyke T, Allison JP, Smyth MJ, Old LJ, Mardis EB, Schreiber RD. Cancer exome analysis reveals a T-cell-dependent mechanism of cancer immunoeediting. Nature 2012, 482:400–404. 10. Aguirre O, Nijman HV, Daemen T. From tumor immunosuppression to eradication: targeting homeostasis and immunity of active effector cells to tumors. Clin Dev Immunol 2011, 2011:93053. 11. Meltman J, Coulkos G, Dranoff G. Cancer immunotherapy comes of age. Nature 2011, 480:480–489.

Published: 15 April 2014
17. Freeman GL, Long AJ, Iwai Y, Bourque K, Chernova T, Nishimura H, Fitz LJ, Melenkovich N, Okazaki T, Byrne MC, BMC N, Schayer et al. Journal for ImmunoTherapy of Cancer 2014, 2:7

18. Chemnitz JM, Parry RV, Nichols KE, June CH, Riley JL: TNF/TNFR family members in costimulation of T cell responses. J Immunol 2004, 173:945–954.

19. Barber DL, Wherry EJ, Masopust D, Zhu B, Allison JP, Sharpe AH, Freeman GJ, Ahmed R: Restoring function in exhausted CD8 T cells during chronic viral infection. Nature 2006, 439:628–671.

20. Topalian SL, Brahmer JR, Camacho LH, Kauh J, Odunsi K, Pitot HC, Hamid O, Bhatia S, Martins R, Colevas AD, Weng WK, Clarke MF, Carlson RW, Stockdale FE, Mollick JA, Sabel MS, Conway TF, Chen FA, Bankert RB: Monoclonal antibodies directed against the T-cell activation molecule CD137 (4-1BB) block human lymphocyte-mediated suppression of tumor xenografts in severe combined immunodeficient mice. J Immunol 2000, 165:362–368.

21. Lee HW, Park SJ, Choi BK, Kim HH, Nam KD, Kwon BS: 4-1BB promotes the survival of CD8+ T lymphocytes by increasing expression of Bcl-2 and Fas-L. J Immunol 2002, 169:4892–4898.

22. Ståck L, Scholz C, Dörken B, Daniel PT: Costimulation by CD137/4-1BB inhibits T cell apoptosis and induces BcI-2 and c-FLIP(Short) via phosphatidylinositol 3-kinase and AKT/protein kinase B. Eur J Immunol 2005, 35:1257–1266.

23. Hernández-Chacon JA, Li Y, Wu RC, Bernetzsch C, Wang Y, Weber J, Huw P, Radvanyi LG: Costimulation through the CD137/4-1BB pathway protects human melanoma tumor-infiltrating lymphocytes from activation-induced cell death and enhances antitumor effector function. J Immunother 2011, 34:236–250.

24. Meleiro J, Shuford WW, Newby SA, Aufrichtig A, Ledbetter JA, Hellström KE, Mittler RS, Chen L: Monoclonal antibodies against the 4-1BB cell activation molecule eradicate established tumors. Nat Med 1997, 3:662–665.

25. Sabel MS, Conway TF, Chen FA, Bankert RB: Monoclonal antibodies directed against the T-cell activation molecule CD137 (4-1BB) block human lymphocyte-mediated suppression of tumor xenografts in severe combined immunodeficient mice. J Immunol 2000, 165:362–368.

26. Brahmer JR, Kim YJ, Zhou Z, Hurtado J, Kim KK, Pickard RT, Kwon BS: Divergent effets of 4-1BB antibodies on antitumor immunity and on tumor-reactive T cell generation. Cancer Res 2011, 71:2031–2037.

27. Lin GH, Liu Y, Ambagala T, Kwon BS, Chak PI, Wang C, Wu W: Evaluating the cellular targets of anti-4-1BB agonist antibody during immunotherapy of a pre-established tumor in mice. PLoS One 2010, 5:e11003.

28. Uno T, Takeda K, Kojima Y, Yoshizawa H, Akiba H, Mittler RS, Gejyo F, Okumura K, Yamagita H, Smyth MJ: Eradication of established tumors in mice by a combination antibody-based therapy. Nat Med 2006, 12:693–698.

29. Takeda K, Kojima Y, Uno T, Hayakawa Y, Teng MW, Yoshizawa H, Yagi H, Gejyo F, Okumura K, Smyth MJ: Combination therapy of established tumors by antibodies targeting immune activating and suppressing molecules. J Immunol 2010, 184:4549–5501.

30. Curnan MA, Kim M, Montalvo W, Al-Shamkhani A, Allison JP: Combination CTLA-4 blockade and 4-1BB activation enhances tumor rejection by increasing CD8+ T-cell infiltration, proliferation, and cytokine production. PLoS One 2011, 6:e19499.

31. Youlin K, Li Z, Xiaodong W, Xuheng L, Hengchen Z: Combination immunotherapy with 4–1 BB and CTLA-4 blockade for the treatment of prostate cancer. Clin Dev Immunol 2012, 2012:439235.

32. Körnt HE, Houtz R, Weikopf K, Goldstein MD, Scheeren F, Czervinski D, Colevas AD, Weng WK, Clarke MF, Carlson RW, Stockdale FE, Mollick JA, Chen L, Levy R: Stimulation of natural killer cells with a CD137-specific antibody enhances trastuzumab efficacy in xenotransplant models of breast cancer. J Clin Invest 2012, 122:1066–1075.

33. Shi W, Siemann DW. Augmented antitumor effects of radiation therapy by 4-1BB antibody (BMS-469492) treatment. Anticancer Res 2006, 26:3445–3463.

34. Verbruggen I, Hagemeyer A, Sharp LL, Galli M, West A, McLaughlin NM, Duret H, Yagita H, Johnstone RW, Smyth MJ, Haynes NW: Radiotherapy increases the permissiveness of established mammary tumors to rejection by immunomodulatory antibodies. Cancer Res 2012, 72:3163–3174.

35. Dubrot J, Palacioz A, Alfarro C, Azepluketa A, Ochoa MC, Rouzaud A, Martinez-Fojo L, Teijeira A, Berrando P, Le Bon A, Hernández-Stibius S, Meleiro J: Intratumoral injection of interferon-α and systemic delivery of agonist anti-CD137 monoclonal antibodies synergize for immunotherapy. J Immunother 2011, 34:125–128.

36. Lee H, Park HJ, Sohn HJ, Kim JM, Kim SJ: Combinatorial therapy for liver metastatic colon cancer: dendritic cell vaccine and low-dose agonistic anti-4-1BB antibody co-stimulatory signal. J Surg Res 2011, 169:403–405.
54. Ascierto PA, Simeone E, Snol M, Fu YX, Melelo I: Clinical experiences with anti-CD137 and anti-CD28 therapeutic antibodies. Semin Oncol 2010, 37:508–516.

55. Hwu W-J: Targeted therapy for metastatic melanoma: from bench to bedside. http://www.hwu.com/hematology-oncology/melanoma-skin-cancer/news/print/hematology-oncology/%B7E71A11-1FD1-4193-A2F7-7C20C6121C4F/Targeted-therapy-for-metastatic-melanoma-From-bench-to-bedside.

56. Pardee AD, McCurry D, Alber S, Hu P, Epstein AL, Storkus WJ: A non-redundant role for OX40 in the competitive fitness of Treg in nonregulatory T cells. J Immunol 2004, 172:3580–3589.

57. Takeda I, Ine S, Killeen N, Ndhlovu LC, Murata K, Satomi S, Sugamura K, Ishii T, Jackson D, Hallahan D, Wang X, Jiang H, Tamura K, Sakaguchi S, Azuma M: The small molecule TGF-β signaling inhibitor SM16 synergizes with agonistic OX40 antibody to suppress established mammary tumors and reduce spontaneous metastasis. Cancer Immunol Immunother 2012, 61:511–521.

58. Hirschhorn-Cymerman D, Rizzuto GA, Mergenhout T, Cohen AD, Avogadi F, Lesokhin AM, Weinberg AD, Wolchok JD, Houghton AN: OX40 engagement and chemotherapy combination provides potent antitumor immunity with concomitant regulatory T cell apoptosis. J Exp Med 2009, 206:103–1116.

59. Curti BD, Kovacsovics-Bankowski M, Morris N, Walker E, Chisholm L, Floyd K, Walker J, Gonzalez I, Meeuwesen T, Fox BA, Moudgil T, Miller W, Haley D, Coffey T, Fisher B, Delaney-Miller L, Rymarchuk N, Kelly T, Crocenzhi T, Bernstein E, Sanborn R, Urba WJ, Weinberg AD: OX40 is a potent immune-stimulating target in late-stage cancer patients. Cancer Res 2013, 73:1189–98.

60. Voo K, Boxer L, Harline ML, Ven LT, Facchinietti V, Arima K, Kow L, Liu YJ: Antibodies targeting human OX40 expand effector T cells and block inducible and natural regulatory T cell function. J Immunol 2013, 191:1641–1650.

61. Porter DL, Levine BL, Kalos M, Bagg A, June CH: Development and characterization of recombinant human Fc:OX40L fusion protein linked via a coiled-coil trimerization domain. Mol Immunol 2007, 44:3112–3121.

62. Nocentini G, Giunchi L, Ronchetti S, Kraus LT, Bartoli A, Moraca R, Migliorati G, Riccardi C: A new member of the tumor necrosis factor/nerve growth factor receptor family inhibits T cell receptor-induced apoptosis. Proc Natl Acad Sci U S A 1997, 94:6216–6221.

63. Nocentini G, Ronchetti S, Petillo MG, Riccardi C: Pharmacological modulation of GITR/GITR system: therapeutic perspectives. Br J Pharmacol 2012, 165:2089–2099.

64. Scher DA, Murphy JT, Wolchok JD: Modulation of GITR for cancer immunotherapy. Curr Op Immunol 2012, 24:217–224.

65. Laci PM, Petillo MG, Ruffini F, Maud A, Bianchini R, Ronchetti S, Migliorati G, Riccardi C, Graziani G, Nocentini G: Glucocorticoid-induced tumor necrosis factor receptor family-related ligand triggering upregulates vascular cell adhesion molecule-1 and intercellular adhesion molecule-1 and promotes leukocyte adhesion. J Pharmacol Exp Ther 2013, 347:164–172.

66. Chattopathyay K, Ramagopal UA, Benczewitz M, Nathenson SG, Almo SC: Evolution of GITR+T immune function: murine GITR+T exhibits unique structural and biochemical properties within the TNFR superfamily. Proc Natl Acad Sci U S A 2008, 105:635–640.

67. Zhou Z, Tone Y, Song X, Fuchs K, Rizzi J, Lear JD, Waldmann H, Tonne M, Greene MI, Murali R: Structural basis for ligand-mediated mouse GITR activation. Proc Natl Acad Sci USA 2008, 105:641–645.

68. Shimizu J, Yamazaki S, Takashashi T, Ishida Y, Sakaguchi S: Stimulation of CD25(+)CD4(+) regulatory T cells through GITR breaks immunological self-tolerance. Nat Immunol 2002, 3:155–162.

69. Stephens GL, McHugh RS, Whitters MJ, Young DA, Luxenberg D, Carreno BM, Collins M, Shevach EM: Engagement of glucocorticoid-induced TNFR family-related receptor on effector T cells by its ligand mediates resistance to suppression by CD4+CD25+ T cells. J Immunol 2004, 173:5008–5020.

70. Cohen AD, Scher DA, Liu C, Li Y, Hirschhorn-Cymerman D, Kim SC, Diab A, Rizziu G, Duan F, Perales MA, Menghouth J, Houghton AN, Wolchok JD: Agonist anti-GITR monoclonal antibody induces melanoma tumor immunity in mice by altering regulatory T cell stability and intra-tumor accumulation. PLoS One 2010, 5:e10436.

71. Turk MJ, Guevara-Patiño JA, Rizzuto GA, Engelhorn ME, Sakaguchi S, Houghton AN: Concomitant tumor immunity to a poorly immunogenic melanoma is prevented by regulatory T cells. J Exp Med 2004, 202:771–782.

72. Ko K, Yamazaki S, Nakamura K, Nishio T, Hirota K, Yamaguchi T, Shimizu J, Nomura T, Chiba T, Sakaguchi S: Treatment of advanced tumors with agonistic anti-GITR mAb and its effects on tumor-infiltrating Foxp3+CD25+CD4+ regulatory T cells. J Exp Med 2005, 202:885–891.

73. Pao J, Kimamura Y, Iwai H, Cao Y, Kikuchi K, Hashiguchi M, Masunaga T, Jiang H, Tamura K, Sakaguchi S, Azuma M: Enhancement of T-cell-mediated antitumor immunity via the ectopically expressed...
glucocorticoid-induced tumour necrosis factor receptor-related ligand (GITRL) on tumours. Immunology 2009, 127:489–499.

92. Schaar DA, Budhu S, Liu C, Byson CF, Malandro NM, Cohen AD, Zhong H, Yang X, Houghton AN, Merghoub T, Wolchok JD: GITR pathway activation abrogates tumor immune suppression through loss of regulatory T cell lineage stability. Cancer Immunol Res 2013, 1:230–331.

93. Cohen AD, Diab A, Perera MA, Wolchok JD, Rizzato G, Merghoub T, Huggins D, Liu C, Turk MJ, Restifo NP, Sakaguchi S, Houghton AN: Agonist anti-GITR antibody enhances vaccine-induced CD8(+) T-cell responses and tumor immunity. Cancer Res 2006, 66:4904–4912.

94. Bulliard Y, Jolicoeur R, Windman M, Rue SM, Ettenberg S, Knee DA, Wilson NS, Dranoff G, Baez D: Activating Fcγ receptors contribute to the antitumor activities of immunoregulatory regulatory-targeting antibodies. J Exp Med 2013, 210:1685–1693.

95. Nishikawa H, Kato T, Hirayama M, Orto Y, Sato E, Harada N, Gnjatic S, Old LJ, Shiku H: Regulatory T-cell-resistant CD8+ T cells induced by glucocorticoid-induced tumor necrosis factor receptor signaling. Cancer Res 2008, 68:5948–5954.

96. Bochkovski D, Lee J, Prutt S, Nair S: Dendritic cells engineered to secrete anti-GITR antibodies are effective adjuvants to dendritic cell-based immunotherapy. Cancer Gene Ther 2009, 16:900–911.

97. Hoffmann C, Starke J, Kaufmann AM, Lodenkemper C, Schneider A, Cichon G: Combining T-cell vaccination and application of agonistic anti-GITR mAb (DTA-1) induces complete eradication of HPV oncogene expressing tumors in mice. J Immunother 2010, 33:136–145.

98. Inoue N, Ikeda H, Tawa I, Wang J, Nishikawa H, Kato T, Shiku H: Glucocorticoid-induced tumor necrosis factor receptor stimulation enhances the multifunctionality of adoptively transferred tumor antigen-specific CD8+ T cells with tumor regression. Cancer Sci 2009, 100:1317–1325.

99. Mitsui J, Nishikawa H, Muraida D, Wang L, Noguchi T, Sato E, Kondo S, Allison JP, Sakaguchi S, Old LJ, Kato T, Shiku H: Two distinct mechanisms of augmented antitumor activity by modulation of immunostimulatory/ inhibitory signals. Clin Cancer Res 2010, 16:2781–2791.

100. Prutt SK, Bochkovski D, de Rosa N, Helye NR, Morse MA, Tyler DS, Dannull J, Fourcade J, Sun Z, Pagliano O, Guillaume P, Luescher IF, Sander C, Kirkwood Derré L, Rivals JP, Jandus C, Pastor S, Rimoldi D, Romero P, Michielin O, Shaer DA, Budhu S, Liu C, Bryson CF, Malandro NM, Cohen AD, Zhong H, Yang X, Houghton AN, Harrop J, Lyn SD, Silverman C, Porter TG, Truneh A, Young PR: Antibody (Mab) agonist of huGITR [abstract]. Proc Natl Acad Sci U S A 2010, 107:10373–10378.

101. Zellweger J, Di Cesare A, Lang K, Marsh H, Yellin M, Harms GM, Figini M, Powell DJ: CD72 costimulation augments the survival and antitumor activity of redirected human T cells in vivo. Blood 2012, 119:696–706.

102. Kelly JM, Darcy PK, Marlbys JL, Godfrey DJ, Copeland NG, Muto T, Yagita H, Okumura K: Characterization of murine CD70 by molecular cloning and mAb. Int Immunol 1998, 10:517–526.

103. Peperzak V, Xiao Y, Veenstra EA, Baez D: CD72 sustains survival of CTLs in virus-infected nonlymphoid tissue in mice by inducing autocrine IL-2 production. J Clin Invest 2010, 120:168–178.

104. Song DG, Ye Q, Pousin M, Harms GM, Figini M, Powell DJ: CD72 costimulation augments the survival and antitumor activity of redirected human T cells in vivo. Blood 2012, 119:696–706.

105. Nair S: Targeting tumor necrosis factor receptor pathways for tumor immunotherapy. J Immunother Therapy Cancer 2014, 2:7.

doi:10.1186/2051-1426-2-7

Cite this article as: Schaar et al.: Targeting tumor-necrosis factor receptor pathways for tumor immunotherapy. Journal for Immunotherapeutic Cancer 2014 2:7.